Pharmaceutical Manufacturer Assertio Therapeutics, Inc. to Pay $3.6 Million to Resolve Allegations that It Violated the False Claims Act in Connection with Marketing its Fentanyl Product

The Justice Department announced on May 5, 2025, that Assertio Therapeutics, Inc., formerly known as Depomed, Inc., a pharmaceutical company headquartered in Lake Forest, Illinois, has agreed to pay $3.6 million to resolve claims that Assertio violated the False Claims Act by causing the submission of false claims for the transmucosal immediate-release fentanyl drug Lazanda for individuals who did not have breakthrough cancer pain.